|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The Ratio of the Absolute Lymphocyte Count to the Absolute Monocyte Count Is Associated with Prognosis in Hodgkin’s Lymphoma: Correlation with Tumor-Associated Macrophages显示文摘 | Young Wha Koh Hyo Jeong Kang Chansik Park Dok Hyun Yoon Shin Kim Cheolwon Suh Heounjeong Go Ji Eun Kim Chul-Woo Kim Jooryung Huh | 2012 | The Oncologist2012，，6： | 2 |
| 2 | Phase Ⅱ study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma:consortium for improving survival of lymphoma(CISL)study显示文摘Background:The response rate and survival improvement for rituximab,a CD20-targeting monoclonal antibody,have been demonstrated in marginal zone lymphoma(MZL)as monotherapy and in combination with chemotherapeutic regimens,yet relapses still occur despite treatment completion.Thus,extending the period of remission in MZL patients remains an essential goal.This multicenter,single-arm,open-label phase II study evaluated the survival efficacy of 2 years of rituximab-maintenance therapy in patients with stage III-IV CD20-positive MZL who had responded to first-line R-CVP(rituximab,cyclophosphamide,vincristine,and prednisolone).The objective of this study was to determine whether rituximab maintenance following R-CVP warrants further investigation.Methods:Prior to rituximab-maintenance therapy,patients received 6-8 cycles of first-line R-CVP therapy for stage III-IV MZL.Rituximab(375 mg/m^(2)),cyclophosphamide(750 mg/m^(2)),and vincristine(1.4 mg/m^(2);maximum 2 mg)were administered via an intravenous infusion on day 1 of each 3-week cycle,while oral prednisolone(100 mg)was given on days 1-5 of each 3-week cycle.The patients who achieved complete response(CR),partial response(PR),or stable disease(SD)to R-CVP treatment,were prescribed rituximab-maintenance therapy which was administered intravenously at a dose of 375 mg/m^(2) every 8 weeks for up to 12 cycles.The primary endpoint was progression-free survival(PFS).Secondary endpoints were overall survival(OS)and treatment safety.Results:47 patients were enrolled,of whom,45(96%)received rituximab-maintenance treatment.Fifteen(33%)patients had nodal MZL.Following R-CVP first-line therapy,20(44%),22(49%),and 3(7%)patients achieved CR,PR,and SD,respectively.After a median follow-up of 38.2 months,their observed 3-year PFS rate was 81%.During the rituximab-maintenance,6 PR and 1 SD patients achieved CR following the administration of R-CVP.Elevated LDH and the presence of B symptoms were found to be significant prognostic factors for PFS(P=0.003)and demonstrated a 3-year OS rate of 90%.Rituximab-maintenance therapy was well tolerated,and the common treatment-emergent adverse events were sensory neuropathy(18%),myalgia(13%),fatigue(9%),and neutropenia(9%).Conclusion: Rituximab-maintenance therapy following first-line R-CVP demonstrated good PFS in patients with stage III-IV MZL, in addition to a favorable toxicity profile. | Sung Yong Oh Won Seog Kim Jin Seok Kim Seok Jin Kim Dok Hyun Yoon Deok-Hwan Yang Won Sik Lee Hyo Jung Kim Ho-Young Yhim Seong Hyun Jeong Jong Ho Won Suee Lee Jee Hyun Kong Sung-Nam Lim Jun Ho Ji Kyung A.Kwon Gyeong-Won Lee Jae Hoon Lee Ho Sup Lee Ho-Jin Shin Cheolwon Suh | 2019 | Cancer Communications2019，39，1： | 2 |
| 3 | Phase I study of weekly docetaxel and cisplatin concurrent with thoracic radiotherapy in stage III non-small-cell lung cancer显示文摘 | Hong-Gyun Wu Yung-Jue Bang Eun Kyung Choi Yong Chan Ahn Young Whan Kim Tae-Hwan Lim Cheolwon Suh Keunchil Park Charn Il Park | 2002 | International Journal of Radiation Oncology Biology Physics2002，，1： | 1 |
| 4 | Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma显示文摘 | Jeong Eun Kim Changhoon Yoo Dae Ho Lee Sang-We Kim Jung-Shin Lee Cheolwon Suh | 2010 | Annals of Hematology2010，，4： | 1 |
| 5 | Bortezomib and the Increased Incidence of Herpes Zoster in Patients with Multiple Myeloma显示文摘 | Seok Jin Kim Kihyun Kim Byung Soo Kim Hyo-Jin Lee Hawk Kim Na-Ri Lee Seung-Hyun Nam Jung Hye Kwon Hyo Jung Kim Sang Kyun Sohn Jong-Ho Won Jae Hoon Lee Cheolwon Suh Sung-Soo Yoon Hye Jin Kim Inho Kim Young-Rok Do Won-Sik Lee Young-Don Joo Ho Jin Shin | 2008 | Clinical Lymphoma & Myeloma2008，，4： | 1 |
| 6 | Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: A multicentre, single-arm, phase 2 trial显示文摘 | Seok Jin Kim Dok Hyun Yoon Hye Jin Kang Jin Seok Kim Seong Kyu Park Hyo Jung Kim Jeeyun Lee Baek-Yeol Ryoo Young Hyeh Ko Jooryung Huh Woo Ick Yang Hee Kyung Kim Soo Kee Min Seung-Sook Lee In-Gu Do Cheolwon Suh Won Seog Kim | 2012 | European Journal of Cancer2012，，17： | 1 |
| 7 | Leptomeningeal Carcinomatosis in Gastric Cancer显示文摘 | Jae-Lyun Lee Yoon-Koo Kang Tae-Won Kim Heung-Moon Chang Gyeong-Won Lee Min-Hee Ryu Eunkyoung Kim Seok-Joong Oh Je-Hwan Lee Sung-Bae Kim Sang-We Kim Cheolwon Suh Kyoo-Hyung Lee Jung-Shin Lee Woo-Kun Kim Sang-Hee Kim | 2004 | Journal of Neuro-Oncology2004，，1： | 1 |
| 8 | Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study显示文摘 | Sukjoong Oh Dong Hoe Koo Min-Jung Kwon Kihyun Kim Cheolwon Suh Chang-Ki Min Sung-Soo Yoon Ho-Jin Shin Deog-Yeon Jo Jae-Yong Kwak Jin Seok Kim Sang Kyun Sohn Young-Don Joo Hyeon-Seok Eom Sung-Hyun Kim Yang Soo Kim ChulSoo Kim Yeung-Chul Mun Hawk Kim Dong S | 2014 | Annals of Hematology2014，，8： | 1 |
| 9 | Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma显示文摘 | Jeong Eun Kim Changhoon Yoo Dae Ho Lee Sang-We Kim Jung-Shin Lee Cheolwon Suh | 2010 | Annals of Hematology2010，，4： | 1 |
| 10 | Should the cut‐off values of the lymphocyte to monocyte ratio for prediction of prognosis in diffuse large B ‐cell lymphoma be changed in elderly patients?显示文摘 | Young Wha Koh Chan‐Sik Park Dok Hyun Yoon Cheolwon Suh Jooryung Huh | 2014 | Eur J Haematol2014，，4： | 1 |
| 11 | Phase II study of radiotherapy with three-dimensional conformal boost concurrent with paclitaxel and cisplatin for Stage IIIB non–small-cell lung cancer显示文摘 | Young Seok Kim Sang Min Yoon Eun Kyung Choi Byong Yong Yi Jong Hoon Kim Seung Do Ahn Sang-wook Lee Seong Soo Shin Jung Shin Lee Cheolwon Suh Sang-We Kim Dong Soon Kim Woo Sung Kim Heon Joo Park Charn Il Park | 2005 | International Journal of Radiation Oncology, Biology, Physics2005，，1： | 1 |
| 12 | Absolute monocyte count predicts overall survival in mantle cell lymphomas: correlation with tumour‐associated macrophages显示文摘 | Young Wha Koh Su‐Jin Shin Chansik Park Dok Hyun Yoon Cheolwon Suh Jooryung Huh | 2014 | Hematol Oncol2014，，： | 1 |
| 13 | Leptomeningeal Carcinomatosis in Gastric Cancer显示文摘 | Jae-Lyun Lee Yoon-Koo Kang Tae-Won Kim Heung-Moon Chang Gyeong-Won Lee Min-Hee Ryu Eunkyoung Kim Seok-Joong Oh Je-Hwan Lee Sung-Bae Kim Sang-We Kim Cheolwon Suh Kyoo-Hyung Lee Jung-Shin Lee Woo-Kun Kim Sang-Hee Kim | 2004 | Journal of Neuro - Oncology (-)2004，，1： | 1 |
| 14 | Outcome of adult severe or very severe aplastic anemia treated with immunosuppressive therapy compared with bone marrow transplantation: Multicenter trial显示文摘 | Myung-Ju Ahn Jung-Hye Choi Young-Yeul Lee Il-Young Choi In-Soon Kim Sung-Soo Yoon Sun-Yang Park Byung-Kook Kim Cheolwon Suh Hee Jeong Son Cheol-Won Jung Jae Hoon Lee Ju-Myung Sung Suck-Ah Im Doyeun Oh So-Young Jung Hwi-Joong Yoon Kyung-Sam Cho Jung-Ae Lee | 2003 | International Journal of Hematology2003，，2： | 1 |
| 15 | Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma显示文摘 | Jeong Eun Kim Changhoon Yoo Dae Ho Lee Sang-We Kim Jung-Shin Lee Cheolwon Suh | 2010 | Annals of Hematology2010，，4： | 1 |
| 16 | Leptomeningeal Carcinomatosis in Gastric Cancer显示文摘 | Jae-Lyun Lee Yoon-Koo Kang Tae-Won Kim Heung-Moon Chang Gyeong-Won Lee Min-Hee Ryu Eunkyoung Kim Seok-Joong Oh Je-Hwan Lee Sung-Bae Kim Sang-We Kim Cheolwon Suh Kyoo-Hyung Lee Jung-Shin Lee Woo-Kun Kim Sang-Hee Kim | 2004 | Journal of Neuro - Oncology (-)2004，，1： | 1 |
| 17 | Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study显示文摘 | Hye Kang Won Kim Seok Kim Je-Jung Lee Deok-Hwan Yang Jin Kim Se-Ryeon Lee Gyeong-Won Lee Hyo Kim Ho Kim Sung Oh Hugh Kim Hyeon-Seok Eom Jooseop Chung Jinny Park Cheolwon Suh Baek-Yeol Ryoo | 2012 | Annals of Hematology2012，，4： | 1 |
| 18 | Real-world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma:amulticenter,retrospective analysis显示文摘Dear Editor,Despite the introduction of novel front-line therapies including rituximab plus high-dose cytarabine followed by consolidative autologous stem cell transplantation(ASCT)and salvage therapy with bendamustine,lenalidomide or bortezomib,mantle cell lymphoma(MCL)is still considered incurable and most patients experience relapse or refractory(RR)disease. | Jun Ho Yi Seok Jin Kim Dok Hyun Yoon Cheolwon Suh Myung Hee Chang Deok Hwan Yang Jae-Cheol Jo Shin Young Hyun Hyeon-Seok Eom Jeong-Ok Lee Ji Hyun Kwon Sang Hoon Han Seung-Shin Lee Jae-Yong Kwak Se Hyung Kim Dae Sik Kim Ji Hyun Lee Sung Yong Oh Hun Mo Ryoo Hyo Jung Kim Won Seog Kim | 2021 | Cancer Communications2021，41，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员